← Search & browse all drugs

saccharomyces boulardii

A07FA02

Forms & Strengths

Capsules: 250 mg, 500 mg
Oral powder for suspension: 250 mg/packet

Adult Dosing

Prevention of antibiotic-associated diarrhea: 250 mg to 500 mg orally 1 to 2 times daily
Treatment of acute infectious diarrhea: 250 mg to 500 mg orally twice daily
Prevention of Clostridium difficile recurrence: 500 mg orally twice daily, adjunct to standard antibiotic therapy

Pediatric Dosing

Infants and children: 250 mg orally 1 to 2 times daily
Safety and efficacy not established in neonates or infants under 1 month

Indications

Prevention and treatment of antibiotic-associated diarrhea
Adjunctive treatment of acute infectious diarrhea
Prevention of recurrent Clostridium difficile infection
Management of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) symptoms

Mechanism of Action

Non-pathogenic probiotic yeast that exerts trophic and anti-inflammatory effects on the intestinal mucosa
Secretes a protease that degrades Clostridium difficile toxins A and B and inhibits their binding to receptors
Stimulates local immune response by increasing secretory IgA production
Competes with pathogenic microorganisms for binding sites and nutrients

Contraindications

Hypersensitivity to Saccharomyces boulardii or yeast preparations
Patients with central venous catheters due to high risk of fungemia
Severely immunocompromised or critically ill hospitalized patients

Adverse Reactions

Flatulence
Constipation
Fungemia (rare, primarily in immunocompromised patients or those with central venous catheters)
Allergic reactions (rash, pruritus, urticaria)

Drug Interactions

Systemic antifungal agents (e.g., fluconazole, ketoconazole, amphotericin B) may diminish the efficacy of Saccharomyces boulardii
Concomitant oral antifungals should be avoided or separated in timing if possible

Curated Content: Needs Vetting Before Put to Clinical Use